Rabies vaccine study seeks to sharpen prevention strategies

NCT ID NCT07399951

Completed Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This completed early-phase study looked at how healthy adults respond to the rabies vaccine when given alone or with an immune-boosting shot (rabies immune globulin). Thirty participants received different combinations of vaccine and immune globulin to compare antibody levels over time. The goal is to better understand how pre-existing antibodies affect vaccine response, which could lead to more effective rabies prevention.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rabies vaccine (Imovax or RabAvert) and rabies immune globulin (HyperRAB)
What this could lead to: If successful, this study could help refine rabies vaccination schedules, potentially reducing doses or improving protection.
What could go wrong: This is a small, early-phase study in healthy people, not patients. Results may not apply to real-world rabies exposure or different populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Washington University School of Medicine Infectious Disease Clinical Trials Unit.

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.